

## Three-Month Paliperidone (Invega Trinza™) Fact Sheet

Invega Trinza, the extended release IM formulation of paliperidone FDA approved May 2015, offers the first quarterly injection option.

### Potential Candidates for Invega Trinza

- To be used only after monthly Invega Sustenna has been established as adequate treatment for at least 4 months
- The last 2 doses of monthly Sustenna should be the same dosage strength before starting Trinza

### Pharmacodynamics/Kinetics

NanoCrystal® technology enables solubility of poorly water-soluble compounds gradually releasing a controlled amount of medication consistently over time

	Invega Sustenna®	Invega Trinza™
Absorption	From day 1 up to 126 days	From day 1 up to 18 months
Time to peak	13 days	30 to 33 days
T <sub>1/2</sub>	25 to 49 days	Deltoid inj: 84 to 95 days <i>Gluteal inj: 118 to 139 days</i>
Metabolism	Hepatic via CYP2D6 & 3A4	
Excretion	Urine (80%), feces (11%)	

### Adverse Reactions


- The safety profile of Invega Trinza is similar to Sustenna
- The most common adverse reactions are
  - Injection site reaction
  - Increased weight
  - Headache
  - Upper respiratory tract infection
  - Akathisia, and Parkinsonism

### Administration

- Administer by IM route only as a single injection (do not divide)
- Prior to injection - shake syringe for at least 15 seconds to ensure a homogenous suspension
- Inject within 5 minutes of shaking vigorously
- Inject slowly, deep into the deltoid or gluteal muscle using only the thin wall needles provided in the pack to reduce the risk of blockage
  - Deltoid injection
    - Use a 1½ inch needle for clients ≥ 90 kg &
    - 1 inch needle for clients < 90 kg
  - Gluteal injection
    - Use a 1½ inch needle regardless of client's weight

### Conversion from monthly Sustenna to 3-month Trinza

- Dosing is based on the client's last dose of Invega Sustenna (using equivalent 3.5 x higher dose)
- Trinza may be administered up to 7 days before or after the next monthly dose date



- Clients may be given the injection up to 2 weeks before or after the 3-month time point

Invega Sustenna® dose	Invega Trinza™ equivalent dose
78 mg	273 mg
117 mg	410 mg
156 mg	546 mg
234 mg	819 mg

### Dosage adjustments

- Dosage adjustments can be made every 3 months in increments within the range of 273 to 819 mg
- Due to the long-acting formulation, client's response to an adjusted dose may not be apparent for several months

### Missed dose

- Missed dose 3 ½ months to 4 months since last injection
  - Administer the previous 3-month dose and continue with normal dosing
- Missed dose 4 months to 9 months since last injection
  - Do not administer the next 3-month dose, follow the re-initiation regimen as below

Last Dose of Invega Trinza™	1 <sup>st</sup> Invega Sustenna, 2 doses 1-week apart (deltoid)		Then Invega Trinza™ (deltoid or gluteal)
Last Dose of Invega Trinza™	Day 1	Day 8	1 month after Day 8
273 mg	78 mg	78 mg	273 mg
410 mg	117 mg	117 mg	410 mg
546 mg	156 mg	156 mg	546 mg
819 mg	156 mg	156	819

- Then resume normal dosing at 3-month intervals
- Missed dose longer than 9 months since last injection
  - Re-initiate treatment with monthly IM paliperidone (Invega Sustenna)
  - Three-month IM paliperidone can be resumed after the patient has been adequately treated with monthly IM paliperidone for at least 4 months

**Formulary status:** PA required

**Please contact BHRS Pharmacy Services for additional information**